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ABSTRACT: Currently, there are no reliable ex vivo models that predict anticancer drug responses in
human tumors accurately. A comprehensive method of mimicking a 3D microenvironment to study effects
of anticancer drugs on specific cancer types is essential. Here, we report the development of a three-
dimensional microfluidic cell array (3D μFCA), which reconstructs a 3D tumor microenvironment with
cancer cells and microvascular endothelial cells. To mimic the in vivo spatial relationship between
microvessels and nonendothelial cells embedded in extracellular matrix, three polydimethylsiloxane (PDMS)
layers were built into this array. The multilayer property of the device enabled the imitation of the drug
delivery in a microtissue array with simulated blood circulation. This 3D μFCA system may provide better
predictions of drug responses and identification of a suitable treatment for a specific patient if biopsy
samples are used. To the pharmaceutical industry, the scaling-up of our 3D μFCA system may offer a novel high throughput
screening tool.
The in vivo microenvironment of mammalian cellspossesses some common characteristics such as continu-
ous nutrient supply and waste removal, maintenance of an
appropriate temperature, short distance between cells and
microvessels, cell−cell communication, minimal surrounding
stress, and the ratio of cell volume to the extracellular fluid
volume greater than one.1,2 However, current in vitro cell
culture techniques used in clinical and pharmaceutical drug
screening or discovery neither provide these conditions nor
simulate the three-dimensional (3D) in vivo microenvironment
of mammalian cells simultaneously. Although the static 3D cell
culture mimics in vivo complexity at some levels, main
limitations of these culture systems include fast nutrient and
O2 depletion as well as accumulation of metabolites and waste
products due to lack of a circulatory mechanism. On the other
hand, animal models often provide good results of drug
pharmacokinetics but seldom yield reliable outcomes of drug
efficacy in human beings.3 In the cases of anticancer drug
development and clinical screening of patient-specific anti-
cancer drugs, lack of accurate 3D in vitro cell/tissue models
becomes a bottleneck.
The process of tumor progression is influenced by the
communication between the tumor cells and the surrounding
cells. Therefore, mimicking the microenvironment of tumor
cells is essential to study tumor growth and regression.4,5
Angiogenesis and metastasis are dependent on the tumor
microenvironment. The continuity of cancer growth relies on
continuous angiogenesis and tumor cell invasion into other
organs via blood vessels.6,7 The conventional 2D cell culture
environment causes cancer cells to adopt unnaturally spreading
morphology, while cancer cells in 3D culture embrace rounded
and clustered morphology similar to tumors in vivo.4,8 Different
drug sensitivities were observed for cells grown as a 2D
monolayer compared with the same cells grown in 3D culture
configurations.9,10 The growth rate of tumor cells in the 3D
environment reflects in vivo tumor growth better than that in
the 2D environment5· Static 3D cell culture techniques lack the
engineered microvessels necessary to closely mimic the in vivo
3D microenvironment.
Miniaturization of a conventional cell culture system with
microfluidic technologies provides an opportunity to model a
three-dimensional physiological or pathological environment. A
wide range of conditions (e.g., multiple drugs) can be screened
simultaneously with high yield on such a platform. Using
reverse transfection and a robotic spotter, the first cell
microarray for 2D cell culture was developed by the Sabatini
group.11,12 When it is used for drug screening and drug action
mechanism discovery, this type of cell microarray generates an
enormous volume of data from one compound screening at one
condition due to the lack of microfluidic systems. To overcome
this limitation, several versions of microfluidic cell arrays for 2D
monolayer cell culture were developed with13,14 or with-
out15−18 microvalves. Their potential applications were
demonstrated broadly from stem cell culture18 and differ-
entiation13 to dynamic gene expression profiling.14 However,
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these microfluidic cell arrays could not accommodate three-
dimensional cell cultures, which are essential to mimic an in
vivo microenvironment.
Recognizing the inherent laminar flow generated in micro-
fluidic channels, researchers have been able to culture cells
encapsulated in 3D matrix on one side of a microchannel and
allow fluid flow on the other side of the channel.19 However,
the device with side-by-side 3D culture and flow in the same
microchannel without the array architecture is not readily
amendable for high throughput screening assays. Additionally,
3D cell microarrays without fluidic components have been
reported with an array of cell and matrix droplets created by a
robotic spotter and cultured on a glass slide.20,21 Without a
simulated microcirculation system, these 3D cell microarrays
were unlikely able to closely mimic the in vivo 3D micro-
environment for high throughput drug screening.
In this study, we developed a 3D microfluidic cell array
(μFCA) consisting of three PDMS (polydimethylsiloxane)
layers to model in vivo microenvironment. The parametric
study using computational fluid dynamics simulation was
performed on the designed geometric variables based on
three-dimensional microfluidic cell array (3D μFCA) to study
their effects on the profiles of flow and nutrient delivery. The
three-layer design enabled 3D hydrogel encapsulation cell
culture in an array of microchambers adjacent to multiple
separated microchannels seeded with endothelial cells to serve
as bioartificial blood vessels. Using this technology, multiple
stimuli including clinical and potential anticancer drugs were
applied on a 3D microtumor array on a single chip to measure
dynamic responses of apoptotic activities. This study has thus
established a potentially high throughput screening method
that combines microfluidic technology and 3D cell culture
techniques to monitor the dynamic responses of potential or
clinical anticancer drugs in a simulated 3D microenvironment
with microcirculation.
■ EXPERIMENTAL SECTION
3D microfluidic cell array (μFCA) consists of: (i) micro-
channels to simulate blood microvessels, (ii) microchambers in
a different layer for 3D cell culturing in extracellular matrix, and
(iii) a membrane with clustered pores at specific locations to
guide the diffusion in between the layers of microchannels and
microchambers. Thus, nutrient supply and waste removal for
cells encapsulated 3D matrix are maintained via diffusion from
and to a continuous flow of fresh medium in the microchannels.
Soft lithography was used to fabricate each layer with
polydimethylsiloxane (PDMS). Briefly, silicon etching was
employed in master making of three layers. A set of food color
dyes was used to verify the diffusion from the top to bottom
layers through clustered pores in the middle layer on a 3D
μFCA. The detailed methods of the device manufacture and
testing are explained in Supporting Information I (ac403899j_-
si_001.pdf).
A computational fluid dynamics (CFD) simulation was
performed in FLUENT (Ansys, Inc.) to investigate the
theoretical similarity of dynamic cell culture conditions
maintained by the 3D μFCA microchambers to interstitial
flow conditions in vivo. The studied geometry was a cross
section of one unit on the device along the thickness with three
parts, one microchamber, one group of pores, and one
microchannel. Detailed procedures of computational modeling
are explained in Supporting Information II (ac403899j_-
si_002.pdf).
Three types of cells were used in this study, human ductal
breast epithelial tumor cell line (T47D), human non-small cell
lung cancer cell line (PC9), and adult human dermal blood
microvascular endothelial cells (HMVEC). Cancer cells were
encapsulated using PuraMatrix hydrogel in its viscous liquid
form and flowed into the bottom microchambers of a 3D
μFCA, followed by cell growth medium in the top channels to
trigger the gel polymerization in the bottom. No visible cell
density variations were observed in the different microchambers
when the cell density of the cell−gel mixture was the same. Cell
culture was maintained by continuous flow in the top channel
using a syringe pump. Short and long-term cell viability in our
μFCA was evaluated using calcein AM, a fluorescence live cell
dye. Structured coculture between PC9 and HMVECs in a 3D
μFCA was achieved by seeding HMVECs in the top
microchannels following the seeding of PC9 cells in hydrogel
in the bottom microchambers. In the case of coculture, cancer
cells were dyed with DiI, a red fluorescence long term cell
tracker. Four apoptotic inducers (i.e., Tarceva, staurosporine,
TNF-α, and colchicines) were applied to compare the caspase-3
activities of PC9 cell cultures in conventional culture dishes
with that in the 3D microenvironment generated in a 3D
μFCA. Caspase-3 activities were measured using DEVD-
Nucview 488, a green fluorescence probe to detect activated
caspase-3. Detailed materials and methods related to biological
experiments in this study are explained in Supporting
Information I (ac403899j_si_001.pdf).
A fully automated epi-fluorescence microscope equipped
with an objective moving in the z direction and a stage
Figure 1. Schematic drawings of tumor microenvironment and 3D microfluidic cell array (μFCA). (a) Tumor microenvironment including cancer
cells, surrounding stromal cells, venules, and arterioles; (b) nutrient and gas transport between microvessels and tumor cells; (c) engineering 3D
microenvironment by a layered structure; (d) schematics of each layer of 3D μFCA; and (e) cross-section view of 3D μFCA. The bottom layer has
microchambers with cancer cells embedded in hydrogel. The middle layer is a permeable membrane with clustered pores. The upper layer has
microchannels with seeded endothelial cells to simulate blood microvessels.
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controller of temperature and CO2 were used to take wide-field
z-stack fluorescence images for 3D cell culture. Time-lapse of
3D images were taken during the drug treatment. Quantitative
fluorescence image analysis was performed after deconvolution
of 3D z-stack images. The detailed methods of 3D image
capture and analysis are explained in Supporting Information I
(ac403899j_si_001.pdf).
■ RESULTS
The tumor microenvironment with blood vessels illustrated in
Figure 1a,b was modeled using a bioengineering approach via a
layered microstructure (Figure 1c). In order to be able to scale
up for future high throughput drug screening, the array concept
was included as illustrated in Figure 1d. Figure 1e is the
schematic drawing of a cross-section view of a 3D μFCA with
an endothelial cell layer over the filter layer to mimic the
physical 3D in vivo structure.
Operation of the 3D μFCA. Figure 2a is a merged image of
AutoCAD drawings of all three masks for: (i) the top layer with
8 white straight microchannels, (ii) the middle porous layer
with 64 groups of micropores represented by purple stars, and
(iii) the bottom layer including 64 microchambers in green. In
order to show the features in top and bottom layers clearly,
different food colors were introduced in a 3D μFCA with a
nonpermeable PDMS middle layer. Features dyed with blue
and green are in the bottom layer while red and yellow
microchannels are on the top (Figure 2b). Scanning electron
microscopy (SEM) images of masters of three layers show that
the diameter of microchambers is 770 μm (Figure 2c) and the
pore size on the middle filter layer (Figure 2d,e) is 40 μm. The
large pore size was chosen aiming to hold the endothelial cells
atop the tumor mass while permitting the maximum exchange
of nutrients and waste products. The vasculature of growing
tumors is known to be very porous compared to normal
vasculurate.22 In a 3D μFCA, pores are grouped and positioned
so that they are right above the microchambers when the
bottom microchamber layer is permanently bonded with the
middle PDMS porous layer. The top layer (Figure 2f) is
composed of 790 μm wide microchannels. The microchannel
width is close to the upper range (>500 μm) of pulmonary
vessel’s diameter.23
One of the main operations in a 3D μFCA is diffusion
between different layers of the device. Such diffusive transport
is critical for communication among cells in different layers. For
this purpose, the diffusion efficiency was tested between layers
using a set of food dyes. Figure 2g includes four frames of a
video captured during the top-to-bottom-layer diffusion test.
When food dyes were introduced through inlets of the top layer
with closed inlets and outlets of the bottom layer, food dyes
reached to the bottom layer within 5 s (Figure 2g). These
results verified that the middle PDMS layer was porous and
diffusion from top to the bottom layer occurred in seconds.
The clustered pores in the middle layer enabling this guided
diffusion between top and bottom layers are displayed in Figure
2h, which shows the cross-section (i.e., side-view) of one unit of
a 3D μFCA including three PDMS layers on a glass substrate to
visually capture the three-dimensional feature of the device.
Diffusion and Microcirculation Profile Using Compu-
tational Fluid Dynamics (CFD) Analysis. Simulation data
conclude that vertical diffusion between different layers plus
convection flow in the top microchannels is sufficient for
Figure 2. Design and fabrication of 3D microfluidic cell arrays. (a) AutoCAD device mask drawing of merged layers, scale bar is 2 mm; (b) top view
of a 3D μFCA with a solid/nonpermeable PDMS middle layer, features dyed with blue and green food colors are in the bottom while red and yellow
channels are in the top layer; SEM images of silicon etched masters of (c) bottom (scale bar is 1 mm), (d) middle, and (f) upper layers (scale bar is 1
mm); (e) SEM image of the enlarged middle layer; master scale bar is 100 μm; (g) frames of a video showing diffusion of food dyes from top to
bottom layers through the middle filter layer in 5 s (two blue stars [∗] point to two channels on the bottom which become blue due to dye diffusion
from the top); side-view of one unit of 3D microfluidic cell arrays (μFCA) captured under a 5× phase contrast objective showing (h1) three PDMS
layers bonded on a glass slide (“M” indicates the middle PDMS layer with clustered pores) and (h2) numbered pores in the middle layer in a dry
brush processed image using Photoshop.
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nutrient delivery and waste removal in the 3D μFCA. There is
an extremely low advective flow at ∼0.1 μm/s in the bottom
microchamber without hypoxia. The decrease in O2 concen-
trations from the microchannel inlet to bottom right corner of
the same microchamber is less than 0.0003%. With 10 to 100
microchambers in a serial connection, there will be no hypoxia
in the last microchamber in our current device with the
microchamber thickness of 100 μm. However, hypoxia
conditions in the late stage of tumors can be mimicked by
increasing the thickness of microchambers in the future.
Detailed results including a figure of computational modeling
are explained in Supporting Information II (ac403899j_-
si_002.pdf).
Reconstructed 3D Cell Images from z-Stack Epi-
fluorescence Images via Deconvolution. To evaluate the
imaging ability of 3D live cell culture in a 3D μFCA using an
epi-fluorescence microscope equipped with an objective
moving in the z-direction, lung cancer cells were dyed with a
green fluorescent long-term cell tracker before hydrogel
encapsulation and then cultured in the microchambers of the
bottom layer of the device for two weeks with initial cell
seeding density of 10 million/mL. Using 1 μm per z-slice over
Figure 3. Lung cancer cells with long fluorescence trackers encapsulated in hydrogel and cultured in a chamber of a 3D μFCA for 15 days, (a) phase
contrast image, (b) 2D projected image after deconvolution of fluorescence z-stack images, and (c) 3D view of (b), where its dimension is 550 × 500
× 70 μm in x (length from left to right), y (depth), and z (thickness from bottom to top) directions.
Figure 4. Short and long-term cell viability in the 3D μFCA culture. (a) Short-term cell viability images including a phase contrast picture of breast
cancer cells embedded in hydrogel and its time-lapse fluorescence green images at 0, 22, and 52 s after the introduction of calcium Am in the top
microchannels. Scale bar is 100 μm. Live cells are fluorescence green; (b) phase contrast and fluorescence red images of long-term culture of lung
cancer PC9 cells in 13 days. The increase of red fluorescence intensity confirmed cell growth; (c) cell growth rate (n = 3) and 3D reconstructed
image of long-term lung cancer cell culture on day 13 after adding calcein AM to verify long-term viability.
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cell aggregates of 70 to 80 μm in depth, deconvolution results
are shown in Figure 3, which includes a projected image
(Figure 3b) and the reconstructed 3D image (Figure 3c) of
cancer cell aggregates cultured in a chamber of the 3D μFCA
on day 15.
High Cell Culture Viability in the 3D μFCA. Short and
long-term cell viability in a 3D μFCA is essential for accurate
drug screening. For a one week culture in a 3D μFCA, viability
of breast cancer T47D cells with initial cell seeding density of
10 million/mL on Day 7 is shown in Figure 4a, which includes
a 10× phase contrast image of T47D cells encapsulated in
PuraMatrix and fluorescence images of cells at 0, 22, and 52 s
after the calcein AM introduction in top microchannels.
Vertical diffusion of calcein AM from top microchannels to
bottom microchambers was indicated by the fluorescence green
signal observed as early as 22 s. At 52 s, most of the cells were
fluorescence green demonstrating high cell viability in the 3D
μFCA. In the long term viability test, PC9 cells were stained
with DiI red fluorescence cell tracker before hydrogel
encapsulation and seeding in a 3D μFCA with initial cell
seeding density of 60 million/mL. Figure 4b shows phase
contrast and fluorescence images of DiI stained PC9 cells on
Day 1, 7, and 13. The gradual increase of red fluorescence
signal indicates the cell growth in the device (Figure 4c). High
cell viability assessed by calcein AM on Day 13 for the long-
term culture in the device is also shown in Figure 4c, which is a
three-dimensional reconstructed green fluorescence image
deconvoluted from a stack of PC9 cell images captured after
calcein AM staining.
Microtumor Cell Aggregates with Mimicked Micro-
vessels in a 3D μFCA. Structured coculture between DiI
prestained cancer cells and microvascular endothelial cells in a
3D μFCA is shown by phase contrast and corresponding
fluorescence images in Figure 5. A fluorescence red cancer cell
aggregate is presented in a microchamber in bottom-focused
images (Figure 5b) while monolayer endothelial cells indicated
by arrows are clearly pictured in the top-focused phase contrast
image (Figure 5c). Thus, a microchannel with endothelial cells
serves as a biomimicked microvessel, and the middle PDMS
membrane with clustered micropores ensures the diffusion-
controlled transport of metabolites and the communication
between cancer cells and their microenvironment. Anticancer
reagents have to diffuse through the mimicked microvessels and
then reach tumor mass, which is a scenario much closer to in
vivo drug delivery.
Profiles of Caspase-3 Activity in Different Culture
Configurations. We demonstrated the potential of the 3D
μFCA for dynamic anticancer drug screening by monitoring
apoptotic response to clinical or potential anticancer drugs.
Figure 6a includes representative time-lapse fluorescence
images showing caspase-3 activities in PC9 cells in conventional
static 2D cultures treated with Tarceva (Tar), staurosporine
(Sta), TNF-α with cycloheximide (TNF-α/CHX), colchicine
(Col), and caspase-3 inhibitors (Cas 3 In) at 0, 3, and 17 h of
stimulation. Results of quantitative fluorescence image analysis
in Figure 6b show that there is a rapid increase of active
caspase-3 in PC9 cells treated by three drugs (Tarceva,
staurosporine, and TNF-α with cycloheximide) in the early
stage of stimulation, followed by a graduated elevation of
activated caspase-3 along the stimulation. However, responses
to colchicine are much slower and lower than the other three
drugs until 12 h after drug stimulations. At 17 h, the
staurosporine treatment led to the highest caspase-3 activity
followed by TNF-α/CHX, colchicine, and Tarceva, in
descending order.
The dynamics of drug responses in conventional static 3D
PC9 encapsulation cultures (Figure 6c) or PC9/microvascular
endothelial cell cocultures (Figure 6d) are very different from
that of 2D cultures. Comparison of 2D (Figure 6b) and 3D
(Figure 6c) PC9 alone cultures shows that caspase-3 activities
were lower in the 3D encapsulation culture. Interestingly, both
the static 3D encapsulation cultures (Figure 6c,d) had higher
drug responses in the early stage of stimulation rather than the
late stage. This phenomenon is vividly demonstrated in Figure
6f,g, which are representative 3D reconstructed images of PC9
cultures and PC9/endothelium cocultures in peptide hydrogel
stimulated by Tarceva, respectively.
In the 3D μFCA culture condition, endothelial and PC9 cells
are structurally cocultured in different layers but communicate
with each other through clustered micropores in the middle
PDMS membrane in between. In drug treated samples, caspase-
3 activities increase slowly but steadily until 6 h when they
reach the highest level (Figure 6e). This is followed by a slight
decrease afterward. Figure 6h is representative 3D recon-
structed images of caspase-3 activities of cocultures in a 3D
μFCA under the stimulation of Tarceva. Comparison of Figure
6d,e demonstrated that cells in structured cocultures using
mimicked in vivo microenvironment have slower and lower
maximum drug responses than the static 3D random coculture
where cells experience drugs directly. The maximum drug
response in structured cocultures in a 3D μFCA was reached at
6 h vs 3 h in the unstructured static 3D coculture in tissue
culture plates. We speculate that the endothelium formed in the
top microchannels worked as a drug barrier layer to delay the
drug delivery.
■ DISCUSSION
In this study, we demonstrated that high viabilities of short
(Figure 4a) and long-term (Figure 4b) cancer 3D cultures
Figure 5. Coculture between PC9 lung cancer cells in the bottom
round microchambers and endothelial cells in the top microchannels
in a 3D μFCA. (a, c) Phase contrast and (b, d) their corresponding
fluorescence images of DiI prestained PC9 cell aggregates in hydrogel
and human microvascular endothelial cells (HMVEC, no staining)
seeded in the microchannels of the top layer. Images at different focus
planes are displayed to show both cell types. Arrows point to some
endothelial cells.
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could be achieved in our 3D μFCA using different initial cell
seeding densities (i.e., 10 and 60 million/mL). Tumor tissues
have a wide range of cellularity from 10% to 90% depending on
cancer types and stages.24−27 The seeding density of 60
million/mL in the bottom microchambers of our current 3D
μFCA gives about 90% cellularity. For a purpose of drug
screening, different cell seeding densities in a 3D μFCA can be
used to achieve the simulation of different stages of cancer.
Additionally, using this 3D μFCA, lung cancer cells grown as
microtumor aggregates in microchambers were structurally
cocultured with endothelial cells in microchannels mimicking
microvessels under continuous flow to simulate blood
circulation (Figure 5). The efficacy of anticancer drugs in
terms of their effects on apoptosis of cancer cells was evaluated
in the 3D μFCA coculture system (Figure 6e,h). In addition,
computational fluid dynamics (CFD) simulation showed that
the 3D μFCA created a microenvironment for cells where the
mechanical stresses are extremely low with about 0.1 μm/s flow
velocity in cell microchambers and the nutrients and waste
products were efficiently transported via diffusion and
extremely low convection (Supporting Information II, Figure
1 (ac403899j_si_002.pdf)).
Conventional cell culture techniques for drug screening are
dominated by 2D cell culture. Recently introduced 3D cell
culture techniques showed the significant impacts of the 3D
tumor structure on cellular microenvironments on cell growth,
cell morphology, gene profile, and drug sensitivities.28,29
Previous microfluidic devices designed potentially for high
throughput drug screening were focused on 2D monolayer cell
culture.11,13,14,16−18 However, it is essential to mimic in vivo
conditions to obtain realistic results of biological processes.30,31
In the previous systems, cancer cells were seeded directly inside
microchannels or microchambers without 3D extracellular
matrix, so cells are in direct contact with fluid flow.14,16,17,32
Such direct flow applies shear stresses on cells which are not
present in vivo except for endothelial cells and duct epithelial
cells (e.g., alveolar and kidney epithelial cells). A simplified
kidney chip and lung chip used mechanical stresses provided by
microfluidic systems in the design.33,34 However, diffusion is
the main transport mechanism in vivo between tissues and
microvessels or capillaries. The 3D μFCA realized the diffusion
process for the transportation of nutrients, metabolic waste
products, and other molecules by the three layer structure. The
flow velocity of 0.1 μm/s in microchambers of a 3D μFCA
obtained by the CFD simulation is similar to the in vivo
interstitial flow, which is 0.1−1 μm/s.35
On the other hand, employing the laminar flow property of
microfluidic channels and micropillars as barriers, a microfluidic
device was managed to have cells embedded in 3D matrix at the
center of a channel and medium flow at both sides of the same
channel.36,37 Lateral diffusion in the same channel maintained
3D cell culture. However, this microfluidic system would allow
low throughput measurements. Using our 3D μFCA, real time
measurements of multiple drug responses in different types of
cancer cells cultured in a 3D microenvironment with simulated
blood vessels could be recorded in single experiments on single
Figure 6. Dynamic caspase-3 activities of anticancer compounds in different culture conditions. (a) Fluorescence images of drug treated PC9 cells for
17 h in 2D conventional culture; quantitative image analysis of drug treated (b) PC9 cells in 2D conventional cell culture (n = 4), (c) PC9 cells in
conventional 3D cultures (n = 4), (d) coculture of PC-9/HMVEC in 3D conventional cell culture (n = 4), and (e) structural coculture of PC-9/
HMVEC in 3D μFCA, where relative caspase-3 activity = log2(FI/FIno‑drug), in which FI means fluorescence intensity (n = 4); 3D reconstructed
fluorescence images of Tarceva treated PC9 cells in (f) 3D conventional culture, (g) 3D conventional coculture of PC9/HMVEC, and (h) structural
coculture of PC9/HMVEC in 3D μFCA.
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chips (Figure 6). Furthermore, by changing the bonding
orientation between the top microchannel layer and the bottom
microchamber layer from currently parallel to orthogonal
alignments, the second generation of 3D μFCA will be a
powerful tool for high throughput drug screening with closely
mimicked 3D microenvironment in an array format. Different
strategies including adding microvalves are under investigation
to prevent drug leakage between microchambers.
In this study, direct visualization and quantitative analysis of
apoptotic responses via caspase-3 activities in PC9 cells
cocultured with HMVECs in 3D μFCA and exposed to four
anticancer drugs were a confirmation of the system versatility
for potential high throughput drug screening (Figure 6).
Dynamic caspase-3 activities in PC9 cells showed that cancer
cells had different drug responses in different culture platforms,
such as static 2D or 3D culture, static 3D coculture, and
structured 3D cocultured in the 3D μFCA with simulated blood
vessels. In the conventional static culture conditions, PC9 cells
had greater drug responses in 2D monolayer culture than that
of cancer cells embedded in 3D matrix (Figure 6b,c). Studies
from other researchers also showed different drug responses of
cancer cells depending on the cell culture environment.4,38
Interestingly, static 3D coculture between PC9 cells and
HMVECs brought the low drug responses back to a similar
level as the 2D monolayer culture (Figure 6b,d). This result
indicates that drug responses are dependent on the 3D
microenvironment and cells themselves. Therefore, it is
essential to construct an in vitro system to mimic an in vivo
tumor microenvironment including proper cell types in order
to obtain reliable anticancer drug responses in drug screening.
The drug response results of the current static 3D
environment are not reliable due to the lack of a circulation
mechanism to remove the waste products and toxic byproducts.
This was confirmed by the different dynamic (e.g., slower and
reduced) drug responses in the structured coculture of lung
cancer cells with microvascular endothelial cells in our 3D
μFCA compared with the static random coculture (Figure
6d,e). We speculate that the attenuated and delayed drug
responses from PC9 and cocultures in our 3D μFCA are caused
by a HMVEC monolayer formed in the top layer of the device,
shown in Figure 5c. Several experimental optimization and
measurements related to the top endothelial layer need to be
performed to achieve microvessels as close to in vivo as possible.
For example, the seeding density of HMVECs and length of the
HMVEC culture before drug testing need to be optimized by
matching diffusive permeability of top endothelial layer to in
vivo data. The diffusive permeability can be measured using
fluorescence labeled dextran molecules.39 In addition, tight
junctions between HMVECs can be verified by VE-cadherin
immunostaining.39 Once the top endothelial layer is fully
optimized, analog phenomena to tumor angiogenesis and
metastasis can be studied in our 3D microfluidic cell arrays.
Although an attempt to construct a layered microfluidic
device was made by stacking a microchannel layer on top of a
two-microchamber layer with an opaque polyester membrane
in the middle,40 this design is not suitable for scaling up to an
array structure for high throughput drug screening due to the
leakage possibility across neighboring microchambers/channels
caused by the property of nonselective perfusion directions of
the polyester membrane, which is permeable vertically and
laterally. The nontransparent semipermeable membrane makes
fast imaging of 3D cell culture in different layers extremely
difficult without confocal microscopy, which is not commonly
used in high throughput drug screening due to its slow
scanning speed. Our 3D μFCA is a pure PDMS device to
overcome limitations mentioned above.
Our novel 3D microfluidic cell arrays established an in vitro
microtumor/tissue array to mimic an in vivo 3D microenviron-
ment with simulated blood vessels. Furthermore, integration of
techniques of microvalve and cell seeding without tubing into
the current design will open the possibility for high-throughput
analysis and clinical translation. Evidence shows that cancer cell
behavior, including progression and drug resistance, is affected
by its host microenvironment consisting of direct contact with
tumor stroma and soluble factors secreted from tumor
stroma.41,42 Therefore, other types of stromal cells besides
endothelial cells (e.g., fibroblasts) in tumor tissues will be
incorporated in the next generation of our 3D microfluidic cell
arrays (μFCA). On the other hand, thin (about 250 μm in
thickness)43,44 and thick (1−2 mm in thickness)45−47 tissue
slides have been cultured successfully in nonarray-format
microfluidic devices with perfusion for hours to a couple of
days depending on tissue types. This encourages us to further
modify our 3D μFCA to accommodate tissue samples (e.g.,
biopsy tissues) directly instead of performing 3D tissue
reconstruction in our next model. It will lead to the clinical
applications of using our 3D μFCA to search for more effective
and personalized medicine in cancer treatments.
In summary, our 3D microfluidic cell array (3D μFCA)
provides a novel technology to mimic an in vivo 3D
microenvironment using an ex vivo platform that is readily
amendable to screen anticancer drugs for a personalized
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